<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">33685</article-id><article-id pub-id-type="doi">10.26442/00403660.2019.11.000337</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Risk Factors for diarrhea associated with Clostridium difficile in patients at a clinical hospital</article-title><trans-title-group xml:lang="ru"><trans-title>Факторы риска диареи, ассоциированной с Clostridium difficile, у пациентов терапевтической клиники многопрофильного стационара</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yarushina</surname><given-names>Y N</given-names></name><name xml:lang="ru"><surname>Ярушина</surname><given-names>Ядвига Николаевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>врач-гастроэнтеролог гастроэнтерологического отд-ния МАУ «ГКБ №40»; ORCID:0000-0002-6333-1291</p></bio><email>yarushina.ya@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kolotova</surname><given-names>G B</given-names></name><name xml:lang="ru"><surname>Колотова</surname><given-names>Галина Борисовна</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., зам. главного врача по медицинской помощи МАУ «ГКБ №40»</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rudnov</surname><given-names>V A</given-names></name><name xml:lang="ru"><surname>Руднов</surname><given-names>Владимир Александрович</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., проф., зав. каф. анестезиологии и реаниматологии ГБОУ ВПО «Уральский государственный медицинский университет» Минздрава России; зам. главного врача по анестезиологии и реанимации МАУ «ГКБ №40»</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bagin</surname><given-names>V A</given-names></name><name xml:lang="ru"><surname>Багин</surname><given-names>Владимир Анатольевич</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., зав. отд-нием анестезиологии и реанимации №5 МАУ «ГКБ №40»</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">City Clinical Hospital №40</institution></aff><aff><institution xml:lang="ru">МАУ «Городская клиническая больница №40»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Ural State Medical University</institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО «Уральский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-11-15" publication-format="electronic"><day>15</day><month>11</month><year>2019</year></pub-date><volume>91</volume><issue>11</issue><issue-title xml:lang="en">VOL 91, NO11 (2019)</issue-title><issue-title xml:lang="ru">ТОМ 91, №11 (2019)</issue-title><fpage>20</fpage><lpage>25</lpage><history><date date-type="received" iso-8601-date="2020-04-16"><day>16</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/33685">https://ter-arkhiv.ru/0040-3660/article/view/33685</self-uri><abstract xml:lang="en"><p>Aim: to identify risk factors for Clostridium difficile infection in patients of a therapeutic clinic in a multidisciplinary hospital. Materials and methods. A retrospective analysis of 110 case histories of patients who were hospitalized in therapeutic departments in the Municipal Autonomous Institution “City Clinical Hospital No. 40” in Yekaterinburg (MAU City Clinical Hospital No. 40) in 2014-2015 was conducted, in which antibiotic therapy has developed diarrhea. According to the results of the study of coprofiltrate on Clostridium difficile (CD), patients were divided into 2 groups: 60 patients with a positive result and 50 patients with a negative result. Results. The proportion of patients with CD infection in the structure of patients of the therapeutic profile of the MAU GKB No.40 for 2014-2015 amounted to 0.42%. Predictors of the risk of developing diarrhea associated with CD infection in patients are: age over 65 years (OS 4.33, 95% CI 1.15-16.20, p=0.028), Charlson comorbidity index more than 2 points (OS 3.05, 95% CI 1.29-7.23, p=0.016), the presence of anemia (OR 2.32, 95% CI 1.07-5.02, p=0.048), chronic dialysis in patients with chronic renal insufficiency (CRF) (OR 8.64, 95% CI 1.05-70.81, p=0.020), patients staying in hospital for more than 5 days (OR 3.50, 95% CI 1.57-7.75, p=0.003) and hospitalization of patients in the intensive care unit (ICU) lasting more than 1 day (OS 9.80, 95% CI 1.20-79.47, p=0.011), the use of proton pump inhibitors (PPIs) (OR 2.82, 95% CI 1.12-7.11, p=0.041), antibiotic therapy more than 10 days (OS 39.62, 95% CI 10.85-144.71, p&lt;0.001), more than 1 course of antibacterial therapy (ABT) (OS 2.85, 95% CI 1.20-6.76, p=0.026), the use of ceftriaxone (OR 3.33, 95% CI 1.45-7.63, p=0.006). Logistic regression analysis showed a connection between the use of 3rd generation cephalosporins (OR 6.55, 95% CI 1.18-36.40, p=0.03) and ABT duration (OR 1.89, 95% CI 1.50-2.38, p&lt;0.001) with a risk of developing diarrhea associated with CD. Conclusions. The use of cephalosporins of the 3rd generation and long - term antibacterial therapy are independent risk factors for the development of diarrhea associated with Clostridium difficile in patients of the therapeutic clinic of a multidisciplinary hospital.</p></abstract><trans-abstract xml:lang="ru"><p>Цель: выявить факторы риска Clostridium difficile инфекции у пациентов терапевтической клиники в многопрофильном стационаре. Материалы и методы. Проведен ретроспективный анализ 110 историй болезни пациентов, находившихся на стационарном лечении в отделениях терапевтического профиля в МАУ «Городская клиническая больница №40» Екатеринбурга (МАУ «ГКБ №40») в 2014-2015 гг., у которых на фоне проведения антибактериальной терапии развилась диарея. По результатам данных, полученных при исследовании копрофильтрата на Clostridium difficile (CD), пациентов разделили на 2 группы: 60 пациентов с положительным результатом и 50 пациентов с отрицательным результатом. Результаты. Удельный вес больных с CD-инфекцией в структуре пациентов терапевтического профиля МАУ «ГКБ №40» за 2014-2015 гг. составил 0,42%. Предикторами риска развития диареи, ассоциированной с CD-инфекцией, у пациентов являются возраст старше 65 лет [отношение шансов (ОШ) 4,33, 95% доверительный интервал (ДИ) 1,15-16,20, р=0,028], индекс коморбидности Charlson более 2 баллов (ОШ 3,05, 95% ДИ 1,29-7,23, р=0,016), наличие анемии (ОШ 2,32, 95% ДИ 1,07-5,02, р=0,048), проведение хронического диализа у пациентов с хронической почечной недостаточностью (ОШ 8,64, 95% ДИ 1,05-70,81, р=0,020), пребывание пациентов в стационаре более 5 сут (ОШ 3,50, 95% ДИ 1,57-7,75, р=0,003) и госпитализация пациентов в отделение реанимации и интенсивной терапии длительностью более 1 сут (ОШ 9,80, 95% ДИ 1,20-79,47, р=0,011), применение ингибиторов протонной помпы (ОШ 2,82, 95% ДИ 1,12-7,11, р=0,041), проведение антибактериальной терапии (АБТ) более 10 сут (ОШ 39,62, 95% ДИ 10,85-144,71, р&lt;0,001), проведение более чем 1 курса АБТ (ОШ 2,85, 95% ДИ 1,20-6,76, р=0,026), применение цефтриаксона (ОШ 3,33, 95% ДИ 1,45-7,63, р=0,006). Логистический регрессионный анализ показал связь применения цефалоспоринов III поколения (ОШ 6,55, 95% ДИ 1,18-36,40, р=0,03) и длительности АБТ (ОШ 1,89, 95% ДИ 1,50-2,38, р&lt;0,001) с риском развития диареи, ассоциированной с CD. Заключение. Независимыми факторами риска развития диареи, ассоциированной с Clostridium difficile, у пациентов терапевтической клиники многопрофильного стационара являются применение цефалоспоринов III поколения и длительное проведение АБТ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Clostridium difficile</kwd><kwd>risk factors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>факторы риска</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Pepin J, Valiquette M.E, Alary P, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. Clostridium difficile - associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171(5):466-72. doi:10.1503/cmaj.1041104</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lessa F.C, Mu Y, Bamberg W.M, Beldavs Z.G, Dumyati G.K, Dunn J.R, Farley M.M, Holzbauer S.M, Meek J.I, Phipps E.C, Wilson L.E, Winston L.G, Cohen J.A, Limbago B.M, Fridkin S.K, Gerding D.N, Mc-Donald L.C. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-34. doi:10.1056/NEJMoa1408913</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kurti Z, Lovasz B.D, Mandel M.D, Csima Z, Golovics P.A, Csako B.D, Mohas A, Gönczi L, Gecse K.B, Kiss L.S, Szathmari M, Lakatos P.L. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol. 2015;21(21):6728-35. doi:10.3748/wjg.v21.i21.6728</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Shivashankar R, Khanna S, Kammer P.P, Harmsen W.S, Zinsmeister A.R, Baddour L.M, Pardi D.S. Clinical factors associated with development of severe - complicated Clostridium difﬁcile infection. Clin Gastroenterol Hepatol. 2013;11(11):1466-71. doi:10.1016/j.cgh.2013.04.050</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Shivashankar R, Khanna S, Kammer P.P, Harmsen W.S, Zinsmeister A.R, Baddour L.M, Pardi D.S. Clinical predictors of recurrent Clostridium difﬁcile infection in out - patients. Aliment Pharmacol Ther. 2014;40(5): 518-22. doi:10.1111/apt.12864</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Gash K, Brown E, Pullyblank A. Emergency subtotal colectomy for fulminant Clostridium difficile colitis - is a surgical solution considered for all patients? Ann R Coll Surg Engl. 2010;92(1):56-60. doi:10.1308/00358 8410X12518836439164</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Slimings C, Riley T.V. Antibiotics and hospital - acquired Clostridium difficile infection: update of systematic review and meta - analysis. J Antimicrob Chemother. 2014;69(4):881-91. doi:10.1093/jac/dkt477</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Oh S.E, Lee S.M, Lee Y-K, Choi S.R, Choi M-J, Kim J-K, Song Y.R, Kim S.J, Park T.J, Kim S.G, Oh J, Suh.JW, Yoon J-W, Koo J-R, Kim H.J, Noh J.W. Clostridium difficile - associated diarrhea in dialysis patients. Kydney Res Clin Pract. 2013;32(1):2731. doi:10.1016/j.krcp.2012.12.002</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Gweon T.G, Choi M.G, Baeg M.K, Lim C.H, Park J.M, Lee I.S, Kim S.W, Lee D.G, Park Y.J, Lee J.W. Hematologic diseases: High risk of Clostridium difficile associated diarrhea. World J Gastroenterol. 2014;20(21):6602-7. doi:10.3748/wjg.v20.i21.6602</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Nitzan O, Elias M, Chazan B, Raz R, Saliba W. Clostridium difficile and inflammatory bowel disease: Role in pathogenesis and implications in treatment. World J Gastroenterol. 2013;19(43):7577-85. doi:10.3748/wjg. v19.i43.7577</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Hainesa С.F, Moorea R.D, Bartletta J.G, Searsa C.L, Cosgrovea S.E, Carrollb K, Gebo K.A. Clostridium difficile in a HIV-Infected Cohort: Incidence, Risk Factors, and Clinical Outcomes. AIDS. 2013;27(17):2799-807. doi:10.1097/01.aids.0000432450.37863.e9</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Bone R.C, Sibbald W.J, Sprung C.L. The ACCPSCCM consensus conference on sepsis and organ failure. Chest. 1992;101(6):1481-3. doi:10.1378/chest.101.6.1481</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Charlson M.E, Pompei P, Ales K.L, Mac Kenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi:10.1016/0021-9681 (87)90171-8</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Asempa T.E, Nicolau D.P. Clostridium difficile infection in the elderly: an update on management. Clinical Interventions in Aging. 2017;12:1799-809. doi:10.2147/CIA.S149089</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Othman F, Crooks C.J, Card T.R. The risk of Clostridium difficile infection in patients with pernicious anaemia: a retrospective cohort study using primary care database. United European Gastroenterology J. 2017; 5(7):959-66. doi:10.1177/2050640617695697</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Dallman P.R. Iron deficiency and the immune response. Am J Clin Nutr. 1987;46(2):329-34. doi:10.1093/ajcn/46.2.329</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Helyar L, Sherman A.R. Iron deficiency and interleukin 1 production by rat leukocytes. Am J Clin Nutr. 1987;46(2):346-52. doi: 10.1093/ajcn/46.2.346</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Dudzicz S, Adamczak M, Więcek A. Clostridium Difficile Infection in the Nephrology Ward. Kidney Blood Press Res. 2017;42(5):844-52. doi: 10. 1159/000484428</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of Immune Dysfunction in End - stage Renal Disease. Clin J Am Soc Nephrol. 2008;3(5):1526-33. doi: 10.2215/CJN.00950208</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Trifan A, Stanciu C, Girleanu I, Stoica O.A, Singeap A.M, Maxim R, Chiriac S.A, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta - analysis. World J Gastroenterol. 2017;23(35):6500-15. doi: 10.3748/wjg.v23.i35.6500</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Janarthanan S, Ditah I, Adler D.G, Ehrinpreis M.N. Clostridium difficile - associated diarrhea and proton pump inhibitor therapy: a meta - analysis. Am J Gastroenterol. 2012;107:1001-10. doi: 10.1038/ajg.2012.179</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Khanna S, Aronson S.L, Kammer P.P, Baddour L.M, Pardi D.S. Gastric acid suppression and outcomes in Clostridium difficile infection: a population - based study. Mayo Clin Proc. 2012;87(7):636-42. doi:10.1016/j.mayocp. 2011.12.021</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Leonard A.D, Ho K.M, Flexman J. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case - control study. Intern Med J. 2012;42(5):591-4. doi:10.1111/j.1445-5994. 2012.02770.x</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Stevens V, Dumyati G, Fine L.S, Fisher S.G, Wijngaarden E. Cumulative Antibiotic Exposures Over Time and the Risk of Clostridium difﬁcile Infection. Clinical Infectious Diseases. 2011;53(1):42-8. doi:10.1093/cid/ cir301</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Slimings C, Riley T.V. Antibiotics and hospital - acquired Clostridium difﬁcile infection: update of systematic review and meta - analysis. J Antimicrob Chemother. 2014;69(4):881-91. doi:10.1093/jac/dkt477</mixed-citation></ref></ref-list></back></article>
